NDA 020886 · Advanz Pharma
Panretin
Alitretinoin · Topical · Retinoid
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Nov 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Feb 2, 1999
Approved uses
1
Original approval plus efficacy supplements
Registered trials
19
10 Phase 3, 0 recruiting
FAERS reports
119
104 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 25, 2025.
1.1 Kaposi’s Sarcoma PANRETIN GEL is indicated for topical treatment of cutaneous lesions in adults with AIDS related Kaposi’s sarcoma (KS). Limitations of Use: PANRETIN GEL is not indicated when systemic anti-KS therapy is required (including more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement) [see Clinical Studies ( 14.1 )] . PANRETIN GEL is a retinoid indicated for the topical treatment of cutaneous lesions in adults with AIDS-related Kaposi’s sarcoma (KS). Limitations of Use : PANRETIN GEL is not indicated when systemic anti-Kaposi’s sarcoma therapy is required.
Mechanism: Alitretinoin (9-cis-retinoic acid) is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptor subtypes (RARα, RARβ, RARγ, RXRα, RXRβ and RXRγ). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. Alitretinoin inhibits the growth of Kaposi’s sarcoma (KS) cells in vitro.
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- PANRETIN · ALITRETINOIN EQ 0.1% BASE · GEL, TOPICAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Alitretinoin" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand DermatitisPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT00124475 · 1,035 participants · Start Dec 2004 · Primary completion Oct 2006
Drug: alitretinoin · For: Hand Dermatoses
Sites: Düsseldorf, Germany
- Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand EczemaPivotal-lookingCompleted
Stiefel, a GSK CompanyIndustry
NCT00817063 · 599 participants · Start Jan 8, 2009 · Primary completion Apr 26, 2012
Drug: alitretinoin; Placebo · For: Eczema
Sites: Birmingham, Alabama; Tucson, Arizona; Fort Smith, Arkansas · 70 sites in all
- A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand EczemaPivotal-lookingCompleted
LEO PharmaIndustry
NCT05259722 · 513 participants · Start Jun 15, 2022 · Primary completion Nov 8, 2023
Drug: Delgocitinib; Toctino · For: Chronic Hand Eczema
Sites: Graz, Austria; Linz, Austria; Calgary, Canada · 102 sites in all
- Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand DermatitisPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT00124436 · 300 participants · Start Mar 2005 · Primary completion Jan 2007
Drug: alitretinoin · For: Hand Dermatoses
Sites: Düsseldorf, Germany
- Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand DermatitisPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT00309621 · 250 participants · Start Apr 2006 · Primary completion Apr 2007
Drug: alitretinoin · For: Hand Dermatoses
Sites: Edmonton, Canada; Vancouver, Canada; Winnipeg, Canada · 33 sites in all
- Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.Pivotal-lookingStatus unknown
Mahmoud Ramadan mohamed ElkazzazAcademic, hospital or other
NCT05016349 · 160 participants (planned) · Start Aug 2021 · Primary completion Oct 2021
Drug: All trans-retinoic acid; 13-Cis Retinoic Acid plus Tocopherol and 5 more · For: Breast Cancer Female
- Alitretinoin in the Treatment of Chronic Hand EczemaPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT00519675 · 150 participants (planned) · Start May 2007
Drug: alitretinoin · For: Eczema
Sites: Paris, France; Saint-Etienne, France; Berlin, Germany · 4 sites in all
- Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand EczemaPivotal-lookingStatus unknown
University Medical Center GroningenAcademic, hospital or other
NCT03026907 · 116 participants (planned) · Start May 2016 · Primary completion Dec 2019
Drug: Alitretinoin; Azathioprine · For: Hand Eczema
Sites: Groningen, Netherlands
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use23
- drug ineffective22
- drug intolerance9
- headache9
- hypercholesterolaemia8
- treatment failure8
- vomiting8
- drug eruption7
- product use in unapproved indication7
- cough6
- diarrhoea6
- fatigue6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 2 |
| 2013 | 3 |
| 2014 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 9 |
| 2020 | 13 |
| 2021 | 15 |
| 2022 | 23 |
| 2023 | 15 |
| 2024 | 9 |
| 2025 | 12 |
| 2026 | 3 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Panretin (Alitretinoin)
2024 spending
$1.1M
Beneficiaries
69
171 claims
Per beneficiary
$15,280
$98.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $233,931 |
| 2022 | $1,140,951 |
| 2023 | $965,460 |
| 2024 | $1,054,337 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.
Giménez-Arnau AM, Pinter A, Sondermann W, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Interventions for chronic palmoplantar pustulosis.
Obeid G, Do G, Kirby L, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Interventions for hand eczema.
Christoffers WA, Coenraads PJ, Svensson Å, et al. · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- New treatment strategies for hidradenitis suppurativa.
Andersen R, Jemec GB · Drugs Today (Barc) 2016 · Systematic Review
- Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.
Voorberg AN, Kamphuis E, Christoffers WA, et al. · Br J Dermatol 2023 · Randomized Controlled Trial
- Guidelines for diagnosis, prevention and treatment of hand eczema.
Diepgen TL, Andersen KE, Chosidow O, et al. · J Dtsch Dermatol Ges 2015 · Practice Guideline, Systematic Review
Sponsor: Advanz Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.